Daniel Greenwald, MD
Gastroenterology · Providence, RINPI 1578902417
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,925 of the $3,613 with a category attached, or 81.0%. Beone Medicines USA, Inc. accounts for 81.0% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $2,973, 7.7 times the $384 reported in 2019.
Across 30 payments — averaging $120.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beone Medicines USA, Inc.$3K
- AbbVie$265
- Boston Scientific$228
- Johnson & Johnson$89
- Takeda Pharmaceuticals U.S.A., Inc.$34
- Merck$25
- plus $47 from 3 others
What the payments were for
- Consulting fees$2,92581%
- Travel & lodging$1424%
- Food & beverage$53115%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beone Medicines USA, Inc. | 1 | $2,925 |
| AbbVie | 17 | $265 |
| Boston Scientific | 2 | $228 |
| Johnson & Johnson | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Merck | 2 | $25 |
| Novo Nordisk | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$2,925
- GENERAL - THERAPIES$142
How this compares
$3,613 in reported general payments places this provider in the 55th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 133 | $2,733 |
| Omeprazole | 181 | $2,526 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 29 | $1,798 |
| CholestyramineCholestyramine (With Sugar) | 13 | $631 |
| Nadolol | 13 | $406 |
| Pantoprazole Sodium | 23 | $335 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Providence
- Thomas SepeProvidence$307K
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Breton RousselProvidence$50K
- Alan EpsteinProvidence$36K
- Samir ShahProvidence$28K
- Lisa MuellerProvidence$25K
- Nabil ToubiaProvidence$20K
- Thaer AbdelfattahProvidence$17K
- Eric NewtonProvidence$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.